Clifford E. Kashtan (2020) An update on current and potential genetic insights and diagnosis of Alport syndrome, Expert Opinion on Orphan Drugs, 8:6, 179-188, DOI: 10.1080/21678707.2020.1784722

Gross, O., Tönshoff, B., Weber, L. T., Pape, L., Latta, K., Fehrenbach, H., Lange-Sperandio, B., Zappel, H., Hoyer, P., Staude, H., König, S., John, U., Gellermann, J., Hoppe, B., Galiano, M., Hoecker, B., Ehren, R., Lerch, C., Kashtan, C. E., Harden, M., … German Pediatric Nephrology (GPN) Study Group and EARLY PRO-TECT Alport Investigators (2020). A multicenter, randomized, placebo-controlled, double-blind phase 3 trial with open-arm comparison indicates safety and efficacy of nephroprotective therapy with ramipril in children with Alport's syndrome. Kidney international, 97(6), 1275–1286. https://doi.org/10.1016/j.kint.2019.12.015

Weinstock, B. A., Feldman, D. L., Fornoni, A., Gross, O., Kashtan, C. E., Lagas, S., Lennon, R., Miner, J. H., Rheault, M. N., Simon, J. F., & Workshop Participants (2020). Clinical trial recommendations for potential Alport syndrome therapies. Kidney international, 97(6), 1109–1116. https://doi.org/10.1016/j.kint.2020.02.029

Kashtan CE. Alport Syndrome: Achieving Early Diagnosis and Treatment. Am J Kidney Dis. 2020;S0272-6386(20)30734-4. doi:10.1053/j.ajkd.2020.03.026

Rheault MN, et al. The Importance of Clinician, Patient and Researcher Collaborations in Alport Syndrome. Pediatr Nephrol. 2020 May;35(5):733-742.

Rheault MN, Smoyer WE. Long-term ACE Inhibition in Alport Syndrome: Are the Benefits Worth the Risks? Kidney Int. 2020 Jun;97(6):1104-1106.

Kashtan CE. Renal Transplantation in Patients With Alport Syndrome: Patient Selection, Outcomes, and Donor Evaluation. Int J Nephrol Renovasc Dis. 2018 Oct 16;11:267-270.

Gross O, Kashtan CE, Rheault MN, et al. A Multicenter, Randomized, Placebo-Controlled, Double-Blind Phase 3 Trial With Open-Arm Comparison Indicates Safety and Efficacy of Nephroprotective Therapy With Ramipril in Children With Alport's Syndrome. Kidney Int​​​​​​. 2020 Jun;97(6):1275-1286. 

Weinstock BA, Kashtan CE, Rheault MN, et al. Clinical Trial Recommendations for Potential Alport Syndrome Therapies. Kidney Int. 2020 Jun;97(6):1109-1116.

Kashtan CE. Alport syndrome: facts and opinions. F1000Res. 2017;6:50.

Gross O, Kashtan CE, Rheault MN, et al. Advances and unmet needs in genetic, basic and clinical science in Alport syndrome: report from the 2015 International Workshop on Alport Syndrome. Nephrol Dial Transplant. 2016;32(6):916-924.

Kashtan CE. Renal transplantation in patients with Alport syndrome: patient selection, outcomes, and donor evaluation. Int J Nephrol Renovasc Dis. 2018;11:267-270.

Kashtan CE, Ding, J., Garosi, G., Heidet, L., Massella, L., Nakanishi, K., . . . Gross, O. (2018). Alport syndrome: A unified classification of genetic disorders of collagen IV α345: A position paper of the Alport Syndrome Classification Working Group. Kidney International,93(5), 1045-1051.

Phelan, P. J., Rheault MN. (2017). Hearing loss and renal syndromes. Pediatric Nephrology,33(10), 1671-1683. doi:10.1007/s00467-017-3835-9

Savige J, Colville D, Rheault MN, et al. Alport Syndrome in Women and Girls. Clin J Am Soc Nephrol. 2016;11(9):1713-20.